Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials-Reference-Cited by-同舟云学术

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

Published:2016-12 Issue:12 Volume:17 Page:1743-1754
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Long Georgina V,Grob Jean-Jacques,Nathan Paul,Ribas Antoni,Robert Caroline,Schadendorf Dirk,Lane Stephen R,Mak Carmen,Legenne Philippe,Flaherty Keith T,Davies Michael A

Publisher

Elsevier BV

Subject

Oncology

Reference34 articles.

1. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

2. NRAS mutation status is an independent prognostic factor in metastatic melanoma;Jakob;Cancer,2012

3. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma;Long;J Clin Oncol,2011

4. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations;Flaherty;N Engl J Med,2012

5. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib;Long;J Clin Oncol,2016

Cited by 277 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liquid biopsy for diagnostic and prognostic evaluation of melanoma;Frontiers in Cell and Developmental Biology;2024-08-02

2. An Automated Real-Time PCR Assay versus Next-Generation Sequencing in the Detection of BRAF V600 Mutations in Melanoma Tissue Samples;Diagnostics;2024-07-30

3. Curing Stage IV Melanoma: Where Have We Been and Where Are We?;American Society of Clinical Oncology Educational Book;2024-06

4. Alantolactone enhances the sensitivity of melanoma to MAPK pathway inhibitors by targeting inhibition of STAT3 activation and down-regulating stem cell markers;Cancer Cell International;2024-05-31

5. SEOM-GEM clinical guidelines for cutaneous melanoma (2023);Clinical and Translational Oncology;2024-05-15